Hung et al identified risk factors for anemia in patients treated for viral hepatitis C. The authors are from Chang Gung University in Kaohsiung, Taiwan.
Antiviral therapy: interferon-alpha-2b plus ribavirin
Severe anemia was defined as a hemoglobin < 10 g/dL.
Parameters:
(1) age in years
(2) gender
(3) platelet count
(4) body weight
Parameters |
Findings |
Points |
age in years |
< 50 years |
0 |
|
>= 50 years |
1 |
gender |
male |
0 |
|
female |
1 |
platelet count |
>= 150,000 per µL |
0 |
|
< 150,000 per µL |
1 |
body weight |
>= 65 kilograms |
0 |
|
< 65 kilograms |
1 |
total number of risk factors =
= SUM(points for all 5 parameters)
Interpretation:
• minimum number of risk factors: 0
• maximum number of risk factors: 4
• The risk of anemia increases with the number of risk factors present.
The time of severe anemia was significantly correlated with a sustained virologic response (absence of viral RNA at 24 weeks post-treatment), especially in patients with HCV genotype 1.
Purpose: To identify a patient who is at risk for developing severe anemia durng antiviral therapy for viral hepatitis C based on the study of Hung et al.
Specialty: Hematology Oncology, Clinical Laboratory, Pharmacology, clinical
Objective: risk factors, pharmacogenetics, comorbid conditions
ICD-10: D60, D61, B15, B16, B17, B19,